Table.
Adverse Events Within the First 6 Weeks After HER2-CAR VST Infusion
| Adverse Event | No. (%) of Patients (N = 17) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Probably related | |||
| Central nervous system | 0 | 0 | 0 |
| Headache | 1 (6) | 0 | 0 |
| Seizure | 2 (12) | 0 | 0 |
| Unrelated | |||
| Hematologic toxic effects | |||
| Anemia | 1 (6) | 0 | 0 |
| Lymphopenia | 7 (41) | 2 (12) | 0 |
| Neutropenia | 2 (12) | 0 | 1 (6) |
| Thrombocytopenia | 1 (6) | 0 | 0 |
| Nonhematologic toxic effects | |||
| General | |||
| Anorexia | 1 (6) | 0 | 0 |
| Fatigue | 0 | 1 (6) | 0 |
| Somnolence | 1 (6) | 0 | 0 |
| Weakness | 2 (12) | 1 (6) | 0 |
| HEENT | |||
| Eye paralysis, lateral | 1 (6) | 0 | 0 |
| Gastrointestinal | |||
| Nausea | 2 (12) | 0 | 0 |
| Diarrhea | 1 (6) | 0 | 0 |
| Constipation | 1 (6) | 0 | 0 |
| Vomiting | 2 (12) | 0 | 0 |
| Cardiac | |||
| Bradycardia | 1 (6) | 0 | 0 |
| Respiratory | |||
| Atelectasis | 1 (6) | 0 | 0 |
| Pain | |||
| Extremity | 1 (6) | 0 | 0 |
| Bone | 1 (6) | 0 | 0 |
| Myalgia | 1 (6) | 0 | 0 |
| Musculoskeletal | |||
| Edema, localized | 1 (6) | 0 | 0 |
| Fracture | 1 (6) | 0 | 0 |
| Central nervous system | |||
| Headache | 0 | 2 (2) | 0 |
| Seizure | 1 (6) | 0 | 0 |
| Gait disturbance | 2 (12) | 0 | 0 |
| Memory impairment | 1 (6) | 0 | 0 |
| Tremors | 1 (6) | 0 | 0 |
| Cerebral edema | 0 | 0 | 1 (6) |
| Hydrocephalus | 0 | 1 (6) | 0 |
| Infectious | |||
| Urinary tract infection | 1 (6) | 0 | 0 |
| Laboratory test results | |||
| Elevated ALT | 1 (6) | 0 | 0 |
| Elevated AST | 1 (6) | 0 | 0 |
| Hyperbilirubinemia | 1 (6) | 0 | 0 |
| Hyperkalemia | 1 (6) | 0 | 0 |
| Hypernatremia | 1 (6) | 0 | 0 |
| Hyponatremia | 1 (6) | 1 (6) | 0 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HEENT, head, ears, eyes, nose, and throat; HER2-CAR VST, HER2–chimeric antigen receptor virus-specific T cell.